Transaction overview
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet recorded the sale of 6,958 shares of the company's common stock on February 13, 2026. The shares changed hands at prices between $302.55 and $314.60, producing proceeds of approximately $2.16 million. According to a Form 4 filed with the Securities and Exchange Commission, the disposition was executed to satisfy minimum statutory tax withholding obligations.
Performance-based award and vesting
The stock sale followed the vesting of a performance-based stock unit (PSU) award. On February 12, 2026, Greenstreet was credited with 14,209 shares of Alnylam common stock that carried a reported value of $0 at the time of acquisition. Those shares were granted under the company’s 2018 Stock Incentive Plan on February 27, 2023, and vested upon achievement of the company’s non-GAAP operating income target for fiscal year 2025.
Post-transaction ownership
After completing the sale and the receipt of the vested shares, Greenstreet’s direct ownership in Alnylam stands at 85,662 shares. She additionally holds 407 shares indirectly through a managed account, as reported in the filing.
Recent financial results and analyst commentary
Alnylam reported fourth-quarter 2025 results that combined an earnings beat with a revenue shortfall. The company posted earnings per share of $1.25, ahead of the forecast of $1.19, while revenue totaled $1.1 billion, missing the anticipated $1.15 billion figure.
Analyst reactions have been varied. Freedom Capital Markets upgraded Alnylam’s rating to Buy from Hold, citing exceptional revenue growth from AMVUTTRA in both U.S. and international markets. RBC Capital left an Outperform rating in place but lowered its price target to $450, pointing to potential short-term headwinds while acknowledging strong commercial performance in 2025, including revenue more than doubling and AMVUTTRA gaining market share. BofA Securities likewise maintained a Buy rating and adjusted its price target to $460, highlighting upcoming clinical catalysts including the completion of a phase 2 trial for mivelsiran and the start of a separate trial for Alzheimer’s disease.
Outlook
The insider transaction and the company’s quarterly results together present a mixed signal: a routine tax-covering sale tied to vested compensation on one hand, and a set of operational and commercial indicators that have generated both upgrades and caution from analysts on the other. These developments underscore an active period for Alnylam as investors and analysts weigh recent commercial traction against short-term revenue execution.
Key points
- CEO Yvonne Greenstreet sold 6,958 Alnylam shares on February 13, 2026, for roughly $2.16 million to cover minimum statutory tax withholding.
- Greenstreet received 14,209 vested PSU shares on February 12, 2026, tied to fiscal 2025 non-GAAP operating income goals; those shares were part of a grant from February 27, 2023.
- Alnylam’s Q4 2025 results included an EPS beat and a revenue miss, prompting mixed analyst responses and adjustments to price targets.
Risks and uncertainties
- Revenue execution risk - The company missed revenue expectations for Q4 2025, which could affect near-term market sentiment in the biotechnology and pharmaceuticals sectors.
- Analyst target and sentiment variability - Divergent analyst actions, including downgrades to price targets while maintaining positive ratings, reflect uncertainty about short-term headwinds and potential catalysts in clinical development.